Geroncogenesis: Metabolic changes during aging as a driver of tumorigenesis

Cancer Cell

Volumn 25, Issue 1, 2014, Pages 12-19

  Wu, LindsayE ^a   Gomes, AnaP ^b   Sinclair, DavidA ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPORINAD; METFORMIN; PROTEIN P53; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7;

AGING; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL VIABILITY; ENZYME ACTIVITY; GENE MUTATION; GLYCOLYSIS; HOMEOSTASIS; HUMAN; LONGEVITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

AGING; ANIMALS; CARCINOGENESIS; ENERGY METABOLISM; HUMANS;

EID: 84892417925     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.12.005     Document Type: Review

References (80)

1. Alhazzazi T.Y., Kamarajan P., Joo N., Huang J.Y., Verdin E., D'Silva N.J., Kapila Y.L. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011, 117:1670-1678.
2. Alhazzazi T.Y., Kamarajan P., Verdin E., Kapila Y.L. SIRT3 and cancer: tumor promoter or suppressor?. Biochim. Biophys. Acta 2011, 1816:80-88.
3. Almeida A., Bolaños J.P., Moncada S. E3 ubiquitin ligase APC/C-Cdh1 accounts for the Warburg effect by linking glycolysis to cell proliferation. Proc. Natl. Acad. Sci. USA 2010, 107:738-741.
4. Ashraf N., Zino S., Macintyre A., Kingsmore D., Payne A.P., George W.D., Shiels P.G. Altered sirtuin expression is associated with node-positive breast cancer. Br. J. Cancer 2006, 95:1056-1061.
5. Barber M.F., Michishita-Kioi E., Xi Y., Tasselli L., Kioi M., Moqtaderi Z., Tennen R.I., Paredes S., Young N.L., Chen K., et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 2012, 487:114-118.
6. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
7. Bell E.L., Emerling B.M., Ricoult S.J., Guarente L. SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene 2011, 30:2986-2996.
8. Bluemlein K., Grüning N.M., Feichtinger R.G., Lehrach H., Kofler B., Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011, 2:393-400.
9. Bowling A.C., Mutisya E.M., Walker L.C., Price D.L., Cork L.C., Beal M.F. Age-dependent impairment of mitochondrial function in primate brain. J.Neurochem. 1993, 60:1964-1967.
10. Brown K., Xie S., Qiu X., Mohrin M., Shin J., Liu Y., Zhang D., Scadden D.T., Chen D. SIRT3 reverses aging-associated degeneration. Cell Rep. 2013, 3:319-327.
11. +) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012, 15:838-847.
12. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
13. Csibi A., Fendt S.M., Li C., Poulogiannis G., Choo A.Y., Chapski D.J., Jeong S.M., Dempsey J.M., Parkhitko A., Morrison T., et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013, 153:840-854.
14. Dobbin M.M., Madabhushi R., Pan L., Chen Y., Kim D., Gao J., Ahanonu B., Pao P.C., Qiu Y., Zhao Y., Tsai L.H. SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. Nat. Neurosci. 2013, 16:1008-1015.
15. Escande C., Nin V., Price N.L., Capellini V., Gomes A.P., Barbosa M.T., O'Neil L., White T.A., Sinclair D.A., Chini E.N. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes 2013, 62:1084-1093.
16. Faubert B., Boily G., Izreig S., Griss T., Samborska B., Dong Z., Dupuy F., Chambers C., Fuerth B.J., Viollet B., et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth invivo. Cell Metab. 2013, 17:113-124.
17. Feldman J.L., Dittenhafer-Reed K.E., Denu J.M. Sirtuin catalysis and regulation. J.Biol. Chem. 2012, 287:42419-42427.
18. Finley L.W., Carracedo A., Lee J., Souza A., Egia A., Zhang J., Teruya-Feldstein J., Moreira P.I., Cardoso S.M., Clish C.B., et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell 2011, 19:416-428.
19. Firestein R., Blander G., Michan S., Oberdoerffer P., Ogino S., Campbell J., Bhimavarapu A., Luikenhuis S., de Cabo R., Fuchs C., et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008, 3:e2020.
20. Frank S.A. Age of cancer incidence. Dynamics of Cancer: Incidence, Inheritance, and Evolution 2007, 17-35. Princeton University Press, Princeton, NJ.
21. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., Pollak M., Regensteiner J.G., Yee D. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685.
22. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
23. Hagen T.M., Yowe D.L., Bartholomew J.C., Wehr C.M., Do K.L., Park J.Y., Ames B.N. Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase. Proc. Natl. Acad. Sci. USA 1997, 94:3064-3069.
24. Hamanaka R.B., Chandel N.S. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem. Sci. 2010, 35:505-513.
25. Haq R., Shoag J., Andreu-Perez P., Yokoyama S., Edelman H., Rowe G.C., Frederick D.T., Hurley A.D., Nellore A., Kung A.L., et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 2013, 23:302-315.
26. Hasmann M., Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003, 63:7436-7442.
27. Herranz D., Muñoz-Martin M., Cañamero M., Mulero F., Martinez-Pastor B., Fernandez-Capetillo O., Serrano M. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun. 2010, 1:3.
28. Herranz D., Maraver A., Cañamero M., Gómez-López G., Inglada-Pérez L., Robledo M., Castelblanco E., Matias-Guiu X., Serrano M. SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. Oncogene 2013, 32:4052-4056.
29. Hirschey M.D., Shimazu T., Goetzman E., Jing E., Schwer B., Lombard D.B., Grueter C.A., Harris C., Biddinger S., Ilkayeva O.R., et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010, 464:121-125.
30. Hubbard B.P., Gomes A.P., Dai H., Li J., Case A.W., Considine T., Riera T.V., Lee J.E., E S.Y., Lamming D.W., et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013, 339:1216-1219.
31. Hubbi M.E., Hu H., Kshitiz, Gilkes D.M., Semenza G.L. Sirtuin-7 inhibits the activity of hypoxia-inducible factors. J.Biol. Chem. 2013, 288:20768-20775.
32. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
33. Jeong S.M., Xiao C., Finley L.W., Lahusen T., Souza A.L., Pierce K., Li Y.H., Wang X., Laurent G., German N.J., et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 2013, 23:450-463.
34. Kanfi Y., Naiman S., Amir G., Peshti V., Zinman G., Nahum L., Bar-Joseph Z., Cohen H.Y. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012, 483:218-221.
35. Kim H.S., Patel K., Muldoon-Jacobs K., Bisht K.S., Aykin-Burns N., Pennington J.D., van der Meer R., Nguyen P., Savage J., Owens K.M., et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010, 17:41-52.
36. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 1971, 68:820-823.
37. Koltai E., Szabo Z., Atalay M., Boldogh I., Naito H., Goto S., Nyakas C., Radak Z. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech. Ageing Dev. 2010, 131:21-28.
38. Lagopoulos L., Stalder R. The influence of food intake on the development of diethylnitrosamine-induced liver tumours in mice. Carcinogenesis 1987, 8:33-37.
39. Lan F., Cacicedo J.M., Ruderman N., Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J.Biol. Chem. 2008, 283:27628-27635.
40. Lee M.S., Hsu C.C., Wahlqvist M.L., Tsai H.N., Chang Y.H., Huang Y.C. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011, 11:20.
41. Li L., Wang L., Li L., Wang Z., Ho Y., McDonald T., Holyoake T.L., Chen W., Bhatia R. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012, 21:266-281.
42. Ligibel J. Lifestyle factors in cancer survivorship. J.Clin. Oncol. 2012, 30:3697-3704.
43. Lim J.H., Lee Y.M., Chun Y.S., Chen J., Kim J.E., Park J.W. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol. Cell 2010, 38:864-878.
44. Lin S.J., Defossez P.A., Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 2000, 289:2126-2128.
45. Liu P.Y., Xu N., Malyukova A., Scarlett C.J., Sun Y.T., Zhang X.D., Ling D., Su S.P., Nelson C., Chang D.K., et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 2013, 20:503-514.
46. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
47. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F., Hwang P.M. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
48. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
49. Menssen A., Hydbring P., Kapelle K., Vervoorts J., Diebold J., Lüscher B., Larsson L.G., Hermeking H. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc. Natl. Acad. Sci. USA 2012, 109:E187-E196.
50. Mostoslavsky R., Chua K.F., Lombard D.B., Pang W.W., Fischer M.R., Gellon L., Liu P., Mostoslavsky G., Franco S., Murphy M.M., et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006, 124:315-329.
51. Narayan N., Lee I.H., Borenstein R., Sun J., Wong R., Tong G., Fergusson M.M., Liu J., Rovira I.I., Cheng H.L., et al. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature 2012, 492:199-204.
52. Nikiforov A., Dölle C., Niere M., Ziegler M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J.Biol. Chem. 2011, 286:21767-21778.
53. North B.J., Verdin E. Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS ONE 2007, 2:e784.
54. Oberdoerffer P., Michan S., McVay M., Mostoslavsky R., Vann J., Park S.K., Hartlerode A., Stegmuller J., Hafner A., Loerch P., et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008, 135:907-918.
55. Oda H., Okamoto I., Murphy N., Chu J., Price S.M., Shen M.M., Torres-Padilla M.E., Heard E., Reinberg D. Monomethylation of histone H4-lysine 20 is involved in chromosome structure and stability and is essential for mouse development. Mol. Cell. Biol. 2009, 29:2278-2295.
56. Onnis B., Rapisarda A., Melillo G. Development of HIF-1 inhibitors for cancer therapy. J.Cell. Mol. Med. 2009, 13:2780-2786.
57. Ono T., Isobe K., Nakada K., Hayashi J.I. Human cells are protected from mitochondrial dysfunction by complementation of DNA products in fused mitochondria. Nat. Genet. 2001, 28:272-275.
58. Petersen K.F., Dufour S., Befroy D., Garcia R., Shulman G.I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N.Engl. J. Med. 2004, 350:664-671.
59. Portmann S., Fahrner R., Lechleiter A., Keogh A., Overney S., Laemmle A., Mikami K., Montani M., Tschan M.P., Candinas D., Stroka D. Antitumor effect of SIRT1 inhibition in human HCC tumor models invitro and invivo. Mol. Cancer Ther. 2013, 12:499-508.
60. Ptitsyn A., Hulver M., Cefalu W., York D., Smith S.R. Unsupervised clustering of gene expression data points at hypoxia as possible trigger for metabolic syndrome. BMC Genomics 2006, 7:318.
61. Quistorff B., Grunnet N. The isoenzyme pattern of LDH does not play a physiological role; except perhaps during fast transitions in energy metabolism. Aging (Albany NY) 2011, 3:457-460.
62. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
63. Ross J.M., Öberg J., Brené S., Coppotelli G., Terzioglu M., Pernold K., Goiny M., Sitnikov R., Kehr J., Trifunovic A., et al. High brain lactate is a hallmark of aging and caused by a shift in the lactate dehydrogenase A/B ratio. Proc. Natl. Acad. Sci. USA 2010, 107:20087-20092.
64. Sebastián C., Zwaans B.M., Silberman D.M., Gymrek M., Goren A., Zhong L., Ram O., Truelove J., Guimaraes A.R., Toiber D., et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 2012, 151:1185-1199.
65. Sedelnikova O.A., Horikawa I., Zimonjic D.B., Popescu N.C., Bonner W.M., Barrett J.C. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat. Cell Biol. 2004, 6:168-170.
66. Semenza G.L. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:347-353.
67. Serrano L., Martínez-Redondo P., Marazuela-Duque A., Vazquez B.N., Dooley S.J., Voigt P., Beck D.B., Kane-Goldsmith N., Tong Q., Rabanal R.M., et al. The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. Genes Dev. 2013, 27:639-653.
68. Simon M.C. Coming up for air: HIF-1 and mitochondrial oxygen consumption. Cell Metab. 2006, 3:150-151.
69. Trifunovic A., Wredenberg A., Falkenberg M., Spelbrink J.N., Rovio A.T., Bruder C.E., Bohlooly-Y M., Gidlöf S., Oldfors A., Wibom R., et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429:417-423.
70. Trounce I., Byrne E., Marzuki S. Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in ageing. Lancet 1989, 1:637-639.
71. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
72. Van Meter M., Mao Z., Gorbunova V., Seluanov A. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle 2011, 10:3153-3158.
73. Vermulst M., Bielas J.H., Kujoth G.C., Ladiges W.C., Rabinovitch P.S., Prolla T.A., Loeb L.A. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat. Genet. 2007, 39:540-543.
74. Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 2005, 39:359-407.
75. Wang R.H., Sengupta K., Li C., Kim H.S., Cao L., Xiao C., Kim S., Xu X., Zheng Y., Chilton B., et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008, 14:312-323.
76. + levels dictate cell survival. Cell 2007, 130:1095-1107.
77. +) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011, 14:528-536.
78. Yuan J., Minter-Dykhouse K., Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J.Cell Biol. 2009, 185:203-211.
79. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5835.
80. Zhong L., D'Urso A., Toiber D., Sebastian C., Henry R.E., Vadysirisack D.D., Guimaraes A., Marinelli B., Wikstrom J.D., Nir T., et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010, 140:280-293.